- Home
- AVIR
as 05-13-2025 4:00pm EST
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 273.7M | IPO Year: | 2020 |
| Target Price: | $6.00 | AVG Volume (30 days): | 525.1K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.60 - $4.14 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Atea Pharmaceuticals Inc. News
AVIR Breaking Stock News: Dive into AVIR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
7 days ago
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
GlobeNewswire
13 days ago
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
GlobeNewswire
21 days ago
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
GlobeNewswire
a month ago
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
MT Newswires
a month ago
Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen
GlobeNewswire
a month ago
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
GlobeNewswire
2 months ago
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
Compare AVIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVIR Atea Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.